West Pharmaceutical (NYSE: WST) VP exercises RSUs, with shares withheld for tax

Rhea-AI Filing Summary

West Pharmaceutical Services VP & Treasurer Charles Witherspoon reported equity award activity involving restricted stock units and common shares. On February 20, 2026, 60.220 restricted stock units converted into 60.220 shares of common stock on a one-for-one basis, increasing his directly held common shares to 1,429.966.

To cover tax obligations related to the vesting, 22.069 common shares were disposed of at $241.12 per share through a tax-withholding transaction, leaving him with 1,407.897 directly owned common shares. After the transaction, he also directly held 177.644 restricted stock units, which can convert into common stock in the future under the award terms.

Insights

Equity compensation analyst

Routine RSU vesting with tax withholding, modest net share increase.

The activity reflects standard equity compensation mechanics. Restricted stock units vested and converted into 60.220 common shares at no exercise price, consistent with the one-for-one conversion ratio disclosed. This is typical for executive compensation rather than an open-market purchase.

A portion of the newly delivered shares, 22.069, was withheld at $241.12 per share to satisfy tax obligations, classified as a tax-withholding disposition. The reporting person’s direct holdings rose to 1,407.897 common shares and 177.644 restricted stock units, a relatively small change unlikely to alter the overall investment case.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Witherspoon Charles

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		M		60.22	A	(1)	1,429.966	D
Common Stock	02/20/2026		F		22.069	D	$241.12	1,407.897	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(1)	02/20/2026		M			60.22	(2)	(2)	Common Stock	60.22	$0	177.644	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On February 18, 2025, the reporting person was granted 237 restricted stock units, vesting in four equal annual installments (plus dividend equivalents) on February 20th each year.

	/s/ Louis Lalli, as an agent for Charles Witherspoon	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did West Pharmaceutical (WST) report for Charles Witherspoon?

West Pharmaceutical reported that VP & Treasurer Charles Witherspoon had 60.220 restricted stock units convert into 60.220 common shares, and 22.069 of those shares were withheld to cover taxes, leaving him with 1,407.897 directly owned common shares and 177.644 remaining restricted stock units.

Did the West Pharmaceutical (WST) insider transaction involve open-market buying or selling?

The filing shows no open-market buying or selling. Shares came from restricted stock units converting into common stock, with 22.069 shares disposed of solely as tax withholding at $241.12 per share, a typical mechanism to satisfy tax obligations on vesting rather than a discretionary market trade.

How many West Pharmaceutical (WST) common shares does Charles Witherspoon now own directly?

After the reported transactions, Charles Witherspoon directly owns 1,407.897 West Pharmaceutical common shares. This reflects 60.220 shares received from restricted stock unit conversion, offset by 22.069 shares withheld to cover tax liabilities associated with the vesting event on February 20, 2026.

What are the details of the restricted stock units in the West Pharmaceutical (WST) Form 4?

The Form 4 notes that restricted stock units convert into common stock on a one-for-one basis. A prior grant of 237 units, awarded on February 18, 2025, vests in four equal annual installments on February 20 each year, with dividend equivalents accruing during the vesting period.

How many restricted stock units does the West Pharmaceutical (WST) insider still hold?

Following the vesting and conversion activity, the reporting person directly holds 177.644 restricted stock units. These units represent future potential common shares, as they convert into stock on a one-for-one basis according to the company’s previously granted restricted stock unit award terms.

What was the tax-withholding price in the West Pharmaceutical (WST) insider transaction?

The tax-withholding disposition involved 22.069 common shares at a price of $241.12 per share. These shares were delivered to satisfy tax liabilities associated with the restricted stock unit vesting, rather than being sold in a discretionary open-market transaction by the reporting person.